Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Compulsory licences: necessity or threat?

23 May 2013 Comments

news image

Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?

Most Read

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...